The news directly mentions Teva Pharmaceutical (TEVA). The company has received a letter from the FTC, which could potentially have regulatory implications. However, without knowing the contents of the letter, it's difficult to predict the exact impact on the company's stock. Therefore, the score is neutral (0), with high relevance (100) due to the direct mention of the company. The importance is set at 75, considering potential regulatory implications, and the confidence at 80, reflecting the uncertainty about the letter's contents.